BMJ Open

Face-to-face physiotherapy compared with a supported home exercise programme for the management of musculoskeletal conditions: protocol of a multicentre, randomised controlled trial—the REFORM trial

Hannah G Withers,1 Joanne V Glinsky,1,2 Jackie Chu,1 Matthew D Jennings,3 Alison J Hayes,4 Ian J Starkey,5 Blake A Palmer,5 Lukas Szymanek,5 Jackson J Cruwys,6 David Wong,7 Kitty Duong,7 Anne Barnett,8 Matthew J Tindall,8 Barbara R Lucas,9 Tara E Lambert,9 Catherine Sherrington,10 Christopher G Maher,11 Manuela L Ferreira,12 Deborah A Taylor,9 Lisa A Harvey1

ABSTRACT

Introduction Exercise, support and advice are considered core components of management for most musculoskeletal conditions and are typically provided by physiotherapists through regular face-to-face treatments. However, exercise can be provided remotely as part of a home exercise programme, while support and advice can be provided over the telephone. There is initial evidence from trials and systematic reviews to suggest that remotely provided physiotherapy can be used to manage a variety of musculoskeletal conditions safely and effectively.

Methods and analysis The aim of this single-blind randomised controlled non-inferiority trial is to determine whether a supported home exercise programme is as good as or better than face-to-face physiotherapy for the treatment of musculoskeletal conditions. Two hundred and ten participants will be recruited from five public hospitals in Sydney, Australia. Participants will be randomised to either the supported home exercise group or the face-to-face physiotherapy group. Participants allocated to the supported home exercise group will initially receive one face-to-face session with the trial physiotherapist and will then be managed remotely for the next 6 weeks. Participants allocated to the face-to-face physiotherapy group will receive a course of physiotherapy as typically provided in Sydney government hospitals. The primary outcome is function measured by the Patient Specific Functional Scale at 6 weeks. There will be nine secondary outcomes measured at 6 and 26 weeks. Separate analyses will be conducted on each outcome, and all analyses will be conducted on an intention-to-treat basis. A health economic evaluation will be conducted from a health funder plus patient perspective.

Ethics and dissemination Ethical approval was obtained on the 17 March 2017 from the Northern Sydney Local Health District HREC, trial number HREC/16HAWKE/431-RESP/16/287. The results of this study will be submitted for publication to peer-reviewed journals and be presented at national and international conferences. Recruitment commenced in March 2019, and it is anticipated that the trial will be completed by December 2021. This trial will investigate two different models of physiotherapy care for people with musculoskeletal conditions.

Trial registration number CPMP/ICH-135/95

Protocol version The most recent version of the protocol is V.1.2 dated November 2019.

INTRODUCTION

Musculoskeletal conditions are common and include back pain, hip and knee osteoarthritis, whiplash-associated disorders and ankle sprains. Together musculoskeletal conditions cause 21% of the total years lived with disability (second only to mental illness),
placing a great burden on world health.1 In 2015, an estimated 30% of all people had at least one musculoskeletal condition in Australia.2 This figure is reported to be as high as 72% for people aged over 75 years.3 In 2008–2009, costs attributed to musculoskeletal conditions were an estimated $5.7 billion.4,5

Exercise, support and advice are considered core components of management for many musculoskeletal conditions.6–9 Exercise, support and advice are typically provided by physiotherapists through regular face-to-face treatments. However, exercise can be provided remotely as part of a home exercise programme while support and advice can be provided via the telephone. There is initial evidence from trials and systematic reviews to suggest that different forms of remotely provided physiotherapy can be used to manage a variety of musculoskeletal conditions safely and effectively.5–10–18 A move away from reliance on face-to-face physiotherapy has many potential benefits. Adopting new technologies and strategies into physiotherapy management will allow for the delivery of timely and accessible care to those who are in remote or rural locations and those who have significant mobility issues. Another benefit for this method of physiotherapy is its low cost, which might enhance cost-effectiveness from a funder and patient perspective. Increasing remote access and decreasing the cost of physiotherapy may have the added benefit of decreasing the burden on the public health system by decreasing waiting times for publicly funded outpatient physiotherapy.19

This model of care is particularly relevant given the global COVID-19 pandemic, although it was developed pre-pandemic. In Sydney, Australia, and elsewhere, the pandemic has meant that telerehabilitation strategies have been rapidly adopted by many hospital outpatient clinics. This has allowed physiotherapists to support the social isolation policies in place to reduce the spread of COVID-19. Telerehabilitation has enabled physiotherapists to continue to provide services to some of the many patients requiring physiotherapy thereby potentially preventing the escalation of symptoms and presentation to emergency departments at a time of burden for the health system.20

The trial will be highly pragmatic with broad inclusion criteria to capture a range of musculoskeletal conditions for which exercise, support and advice are the basis of evidence-based care. The aim is to determine whether a supported home exercise programme is as effective or better than a course of face-to-face physiotherapy. This will be determined with one primary outcome and nine secondary outcomes. An economic analysis will be run alongside the trial to assess the affordability and value for money of this model of care from a health funder and patient perspective. A process evaluation will also be completed in order to understand the feasibility of delivering physiotherapy through supported home exercise programmes and to explore the perspectives of patients, healthcare professionals and key stakeholders about different models of delivering physiotherapy.

METHODS AND ANALYSIS

Design

A single-blind randomised controlled non-inferiority trial will be undertaken to compare a course of physiotherapy as typically provided in Sydney government hospitals with a supported home exercise programme administered through a smartphone/tablet application (an ‘app’) and supplemented with text messages and two telephone calls. Cost-effectiveness will be evaluated from a health funder and patient perspective.

Participants will be recruited from five tertiary public teaching hospitals in Sydney, Australia: Bankstown Lidcombe Hospital, Blacktown-Mt Druitt Hospital, Campbelltown Hospital, Hornsby Hospital and Liverpool Hospital.

Participants

Two hundred and ten adults with a musculoskeletal condition presenting for a course of physiotherapy or on a waiting list for physiotherapy at one of the five participating hospitals will be recruited.

A person will be eligible to participate if he or she:

► Is 18 years or over and able to provide informed consent in writing.
► Has a musculoskeletal condition. Examples include:
  - Back/neck pain.
  - Hip or knee osteoarthritis.
  - Whiplash-associated disorders.
  - Ankle sprains.
  - Post-fracture.
  - Sporting injury.
  - Post hip or knee replacement.
► Is seeking physiotherapy treatment at the participating hospital.
► Can speak and read English to provide informed consent.
► Is able to participate for 6 weeks and will be available for 6-week and 26-week follow-up assessments.
► Has access to a smartphone with internet connection.
► Is identified by the hospital physiotherapists or trial physiotherapist (study coordinator) to have a condition appropriate for treatment with exercise, support and advice.

A person will be excluded if he or she:

► Is pregnant.
► Has a mental illness that may affect adherence to the trial protocol. This will be determined in consultation with the treating physiotherapists and a review of medical history.
► Is deemed to be at a high risk of falling with home exercises.
► Is at a clinical risk without face-to-face physiotherapy.
► Is on a postoperative exercise regimen prescribed by a surgeon.

Public and patient involvement

Over a 20-year period, patients and the public were involved in the development of the exercise app (www. Withers HG, et al. BMJ Open 2021;11:e041242. doi:10.1136/bmjopen-2020-041242
physiotherapyexercises.com) on which this trial is based.

The primary outcome measure was developed in 199518
with input from patients. All participants for this trial are
patients on a waiting list for outpatient physiotherapy in
one of the five public hospitals involved in this trial. All
participants will be asked to give written informed consent
before being randomised. In order to include the partici-
pants’ perspective in the results of this trial, an outcome
measure asking the participants to self-report their satis-
faction with service delivery will be included. A secondary
process evaluation will also explore participants’ opinions
and experiences of the intervention and trial. A separate
manuscript is being prepared to explain the protocol for
the process evaluation. Participants will be able to access
the published results of this trial.

Recruitment strategy and time frame
Recruitment started in March 2019, and currently, 141
participants have been randomised. Recruitment was
however temporarily ceased on 9 March 2020 because
of the COVID-19 pandemic. It recommenced gradually
from July 2020, once it was considered safe and appro-
riate by the investigators and participating sites and will
continue until 210 participants have been recruited (see
online supplemental appendix table 1 for the timeline of
study).

Potential participants will be screened according to
the inclusion/exclusion criteria from the waiting list
of each outpatient physiotherapy department. This
process will be completed by either the treating phys-
iotherapists or administrative staff of the department
over the telephone. If appropriate, patients will be
given an appointment to attend the outpatient depart-
ment to complete the consent, baseline assessment and
randomisation.

Assignment of intervention
A secure random allocation schedule has been computer
generated by an independent researcher and is stored
off site on a REDCap database. Randomisation is blocked
and stratified by site and duration since onset of injury
(less than 12 weeks vs more than 12 weeks). The alloca-
tion schedule is concealed from potential participants
and from all staff associated with the trial. Randomisation
will occur once a participant has been screened, provided
consent and completed the baseline assessment. A trial
staff member responsible for coordinating the treatments
will log onto REDCap to retrieve the participant’s alloca-
tion. Participants’ assignments will not be disclosed to
the blinded assessors or all but two investigators. Eligible
participants are randomised into one of two groups
namely:

The supported home exercise group
Participants initially receive one face-to-face session with
the trial physiotherapist but are then managed remotely
for the next 6 weeks.

Participants receive a course of face-to-face physiotherapy
by a hospital physiotherapist.

Interventions
Supported home exercise group
Participants allocated to the supported home exercise group
initially receive one face-to-face session with the trial physio-
therapist and then will be managed remotely for the next
6 weeks. During the initial session, the trial physiotherapist
will assess the patient and then prescribe an individualised
6-week home exercise programme consisting of a battery
of 5–10 exercises. This will be delivered to patients’ mobile
devices using a freely available exercise-prescribing app that
authors LAH, JVG and colleagues have developed (www.phys-
iotherapyexercises.com). The number of repetitions and sets
of exercises will be determined by the trial physiotherapist.
Participants will be asked to complete their exercises at least
once every day for the intervention period of 6 weeks. Partic-
ants will record exercise adherence on their app. These
data will be automatically transferred to a password-protected
section of the website, which is accessed by the trial phys-
iotherapist to remotely monitor exercise adherence. The
trial physiotherapist will provide ongoing support through
weekly text messages. The purpose of these text messages
is to encourage adherence to the prescribed exercises and
provide the participants with encouragement and support.
These text messages are generated from a prepaid website
and are scheduled to be sent each week to the participants
in the supported home exercise group. The messages are
not individualised but are designed to be motivating and to
remind participants to continue their exercises. Participants
cannot respond to these text messages (see online supple-
mental appendix table 2 for examples of the text messages).
The participants will also receive a telephone call from the
trial physiotherapist at 2 and 4 weeks to ensure adherence
and provide feedback, support and advice. Participants will
be telephoned more frequently if their exercise adherence
is poor. Participants are also able to contact the trial physio-
therapist on a study mobile phone number or via email at any
time. The trial physiotherapist has the option of providing
an additional face-to-face physiotherapy session if she has any
concerns about a participant’s progress, safety or well-being
that she may become aware of from conversations with the
participant or the trial physiotherapist on the telephone or from any other trial or
hospital staff. Details about all additional text and phone calls
with the intervention participants will be recorded including
the number of text messages and the number and duration of
telephone calls. In addition, the number of failed attempts to
contact participants by telephone will be recorded. Detailed
notes will also be kept regarding participants’ adherence to
their exercise programmes and any advice and support given.
Participants will also be asked to report on whether or not
they received the weekly automated text messages.

Face-to-face physiotherapy group
Participants allocated to the face-to-face physiotherapy group
will receive a course of physiotherapy as typically provided

in Sydney government hospitals. This will be provided by
the hospital physiotherapists and could involve up to three
sessions per week for up to 6 weeks or group classes. The
number of sessions per week and duration of the course of
physiotherapy for each participant will be determined by
the hospital physiotherapist and may be gradually decreased
and completed during the intervention period if a partic-

ipant recovers. This approach has been adopted to mimic
usual practice. The type of physiotherapy provided during
the face-to-face sessions will be determined by the hospital
physiotherapist and may include any combination of manual
therapy, advice, exercise and occasional electrotherapy. In
this way, the trial will be pragmatic and will provide a real-
life comparison of the two models of care. The number of
sessions and type of therapy provided will be recorded and
reported (see online supplemental appendix table 3 for a
detailed description of the intervention as per the Template
for Intervention Description and Replication (TIDieR)
checklist).

Participants in both groups are permitted to continue
with any concomitant treatments for any comorbidities.
Participants in both groups will be asked not to pursue
other sources of physiotherapy for their current muscu-
loskeletal conditions over the 6-week intervention period.

Outcome measures

All outcomes will be collected at baseline, 6 weeks and 26
weeks except one outcome (participant satisfaction with
healthcare service delivery), which will only be collected
at 6 and 26 weeks (see online supplemental appendix
table 4 for the trial visit schedule). Site, duration since
onset of injury (less than 12 weeks vs more than 12 weeks)
and baseline measurements will be used as covariates in
the analyses to increase the precision of the estimates.

The primary outcome will be:

Function as measured by the patient-specific functional scale at 6
weeks

This outcome measure is sensitive to changes that are
important to patients and is used across many different
types of musculoskeletal conditions including cervical spine,
knee and lower back pain. Participants are asked at base-
line to identify up to five functional activities that are most
important to them and which they find difficult to perform.
Participants are then asked to rate each activity at baseline
and 6 weeks on an 11-point scale. The scale ranges from 0 to
10 and indicates the level of difficulty participants have with
each activity due to their condition. Zero indicates that they
are unable to perform the activity and 10 indicates that they
are able to perform the activity at preinjury level. Scores for
each activity are summed and expressed as a percentage of
the total possible score for the participant (determined by
the number of identified activities).

The patient-specific functional scale at 26 weeks
See previous information for details.

Fear of movement and reinjury measured using the Tampa Scale
for Kinesiophobia (TSK) at 6 and 26 weeks

The TSK is a multi-item instrument that quantifies fear of
movement and reinjury. Participants are asked to score 17
items on a scale of 1–4, where a score of 1 indicates ‘strongly
disagree’ and a score of 4 indicates ‘strongly agree’. Items 4, 8,
12 and 16 are reversed where 1 indicates ‘strongly agree’ and
4 indicates ‘strongly disagree’. This instrument has high reli-
ability.22 23

Pain measured using a 0–10 Numerical Rating Scale (NRS) at 6
and 26 weeks

Participants are asked to rate their average pain over the
past 24 hours on a 0–10 NRS anchored at each end with
‘no pain’ and ‘worst pain imaginable’. The NRS for pain
measurement is a valid and reliable tool for measuring
acute and chronic pain.24

Patient global impression of change at 6 and 26 weeks

Participants are asked to rate the change in their condi-
tion on a numerical scale. This scale ranges from nega-
tive seven to positive seven anchored in the middle and at
each end with ‘no change’, ‘very much worse’ and ‘very much
better’, respectively.

Patient satisfaction with healthcare service delivery at 6 weeks

Participants are asked to rate their satisfaction with the
care they have received for their musculoskeletal condi-
tion on an 11-point numerical scale. This scale ranges from
0 to 10 anchored at each end with ‘complete dissatis-
faction’ and ‘complete satisfaction’ with the delivery of
healthcare service.

Health-related quality of life measured using the EuroQol-5D at 6
and 26 weeks

This validated questionnaire has been used in a wide
range of musculoskeletal conditions and requires the
participant to rate their level of problems in five dimen-
sions including mobility, self-care, usual activities, pain
and anxiety/depression. Utility-based quality of life will
be derived from the Australian valuation of this instru-
ment for use in the cost–utility analysis.

Functional performance measured with the function component of
the later life function and disability instrument at 6 and 26 weeks

This standardised 32-item instrument captures participants’
perceptions about their abilities to perform discrete actions
or activities (eg, unscrew the lid of a jar and put on and take
off a coat or jacket). It is suitable for adults of all ages even
though it was specifically designed for adults in later life. This
instrument has good validity and has been recommended
for self-reported data collection.25 The full assessment also
captures life performing tasks and limitations on performing
life performance tasks but only the functional performance
aspect of the assessment will be used. Participants are asked
to rate their difficulties performing each of the 32 actions
or activities on a five-point scale ranging from ‘none’ (ie, no
difficulties performing the activity) to ‘can’t do’. Scores will be
Frequency of performing life tasks measured with the disability component of the later life function and disability instrument at 6 and 26 weeks

This standardised 16-item instrument captures participants’ perceptions about the frequency with which they perform socially defined life tasks such as visiting friends and family in their homes, taking part in recreational activities and travelling with overnight stays. Participants are asked ‘to what extent they feel limited in doing a particular task’. They are provided with the following options: ‘completely’, ‘a lot’, ‘somewhat’, ‘a little’ and ‘not at all’. Scores will be transformed into a 0–100 summary score where a high score indicates a higher level of functioning.

Limitations in capability of performing life tasks measured with the disability component of the later life function and disability instrument at 6 and 26 weeks

This standardised 16-item instrument captures participants’ perceptions about their limitations in performing socially defined life tasks such as visiting friends and family in their homes, taking part in recreational activities and travelling with overnight stays. Participants are asked ‘how often do they do a particular task’. They are provided with the following options: ‘very often’, ‘often’, ‘once in a while’, ‘almost never’ and ‘never’. Scores will be transformed into a 0–100 summary score where a high score indicates a higher level of functioning.

Sample size

A sample size of 210 people is required to provide 80% power for a non-inferiority margin (delta) of −1.5 points on the primary outcome Patient Specific Functional Scale (PSFS) where a positive between-group difference favours the supported home exercise group assuming a 15% loss to follow-up, an SD of 2, a 15% treatment dropout rate, a correlation between baseline and final scores of 0.5 and a conservative estimate that the between-group difference favours the face-to-face group by 0.75 points.

Data analysis

Statistical plan

Data analysis and dissemination of results will occur after the database has been cleaned and locked. All analyses will be conducted on an intention-to-treat basis with these performed and interpreted blinded to treatment group according to a prespecified statistical analysis plan. Separate analyses will be conducted on each outcome.

Non-inferiority analysis

The supported home exercise group will be considered non-inferior to the face-to-face physiotherapy group if the upper limit of the 95% CI associated with the mean between group difference on the PSFS at 6 weeks indicates that supported home exercise versus face-to-face physiotherapy is either better or no worse than 1.5 points out of 10. The non-inferiority cut-off point of 1.5 was decided by the investigators after taking into consideration the likely implications of this amount of difference on function and the cost of the intervention.

Other analyses

The results of all other analyses will be presented as point estimates (with 95% CI) and will not be interpreted with respect to non-inferiority margins (deltas) or statistical significance but instead used to aid the interpretation of the results of the non-inferiority analysis of the primary outcome at 6 weeks. We will not make any adjustments for multiple comparisons; however, we will interpret these findings cautiously taking into account the number of outcomes and the two endpoints. Between-group comparisons of each outcome will be conducted using regression models in which the outcome will be a linear function of a dummy-coded variable representing group membership (supported home exercise group or face-to-face physiotherapy group) and a dummy-coded variable for stratum, specifically site and duration since onset of injury (less than 12 weeks vs more than 12 weeks). Baseline scores will be included in the model to increase statistical precision. If more than 5% of data are missing for a particular analysis, multiple imputation will be used to account for missing data provided the missing at random assumption appears plausible.

Economic evaluation

The economic evaluation will compare the supported home exercise programme with face-to-face physiotherapy and will be conducted from a health funder plus patient perspective, since patients will contribute time and money to the treatments. If supported home exercise is statistically non-inferior to face-to-face physiotherapy, then a cost minimisation analysis will be conducted; otherwise, a cost-effectiveness analysis for the primary and secondary outcomes (patient function at 6 weeks and 26 weeks) will be conducted. A trial-based cost–utility analysis for quality of life outcomes at 26 weeks will also be conducted. The cost of delivering the physiotherapy intervention in the two arms of the trial will be determined using standard microcosting methods. All costs will be collected during the trial period and valued in 2021 Australian dollars. Health funder costs will include physiotherapists’ time and materials where appropriate. Other healthcare utilisation (eg, visits to doctors, exercise physiologists and masseurs) will be determined by patient self-report. Patient costs will include the costs associated with the time to: attend the face-to-face sessions with the physiotherapist (including travel time), receive the telephone calls from the trial physiotherapist and to complete the prescribed home exercise programme. The cost of any equipment purchased will also be included. As in all economic evaluations, the costs captured in this study are likely to be skewed, so nonparametric bootstrap methods will be used for hypothesis testing and interval estimation. In the cost–utility analysis, patient outcomes will be measured in quality-adjusted life years (QALYs)

at 26 weeks, using a standard instrument, the Euro-Quol quality of life questionnaire, the EQ-5D-5L. The incremental cost-effectiveness ratio (ICER) will be determined in Australian Dollars (AUD) per QALY gained. Bootstrapped cost-effect pairs will be plotted on an incremental cost-effectiveness plane and a cost-effectiveness acceptability curve will be generated for the probability of being cost-effective at different thresholds. The robustness of the ICERs will be tested through multiple one-way sensitivity analyses.

Data collection
Baseline data will be collected on paper case report forms (CRFs) and then entered into an electronic database (REDCap) by the trial physiotherapist. The data at 6 and 26 weeks will be collected in one of four ways. Most participants will be guided while they use an online data collection form or the assessor will take responses from participants over the telephone and enter them into the online data collection form for the participant. If the participant prefers a paper copy to be sent in the mail, then the assessor will take responses from the participant over the telephone and enter them into the database while the participants read the questions from the paper copy. Participants will also be given the option to complete the assessment on paper and return the completed forms via an included prepaid envelope. The final option of data collection will allow the participant to complete the online assessment independently by receiving a link via email and completing the questions online without any assistance from the assessor. Regardless of the method used to collect the data, the assessor responsible for interacting with the participant and/or collecting the data over the telephone will be blinded to the treatment. In addition, participants will be reminded at the time of the assessment not to reveal any details regarding their physiotherapy treatments to the assessor. If unblinding occurs, a new blinded assessor will complete the next assessment for that participant. Data for the economic evaluation will be collected over the telephone by an unblinded trial physiotherapist after the 6-week blinded assessment has been completed.

Data storage
All information collected for this trial will have identifying information removed and will be kept confidential and secure. All files containing participants’ personal details will remain at the site where they are collected. The original CRFs will be stored centrally on completion of the trial and will only contain the participants’ ID code. Electronically transcribed data will be stored on the REDCap system managed by the University of Sydney. Access to data will only be granted to the principal investigators and other research staff directly involved in the study. All source documents and trial documentation will be kept in a secure location by the investigators for 15 years or the appropriate retention period according to local regulations.

Data confidentiality
Consent forms, baseline assessments and all files containing participants’ personal details will remain at the site where the participant was recruited. Confidential medical notes will be completed on the electronic medical record system used in public hospitals in Sydney, Australia. All other data, both paper and electronic, will be stored either centrally in a secure location or in the password-protected database managed by the University of Sydney. All data will be deidentified.

Trial monitoring
The study will be overseen and monitored by the research staff who will examine study procedures, ensure data quality and monitor compliance with the study protocol. All protocol violations will also be recorded. An independent Data Safety Monitoring Board will not be used for this trial, and an interim analysis will not be conducted because the intervention is unlikely to cause harm, and the trial is not sufficiently large enough to warrant stopping it early on the grounds of futility. Ethical approval was obtained on 17 March 2017 from the Northern Sydney Local Health District HREC, trial number HREC/16HAWKE/431-RESP/16/287.

All serious adverse events (SAEs) from the time of randomisation to the 26-week assessment will be recorded. These will include any events that result in death, disability, hospitalisation or prolongs existing hospitalisation. The trial physiotherapist will record all the relevant information regarding each SAE including the type of event, the start and stop dates, the action taken and the cause of the event. It will be reported to the principal investigator within 24 hours and reported immediately to the ethics committee irrespective of group allocation. It will also be detailed in the annual report. If a SAE has a significant safety issue, a report will be made to the principal investigator within 72 hours, and the trial will be modified to eliminate the safety issue. In contrast, data on other types of non-serious adverse events will be recorded but not immediately reported to the ethics committee. These data will be collected for both groups by asking participants at 6 and 26 weeks to recall any events related to their condition or the intervention.

Provenance
This trial is registered at the Australian and New Zealand Clinical trial registry. It will be conducted in accordance with the National Health and Medical Research Council’s National Statement on Ethical Conduct in Human Research and the Note for Good Clinical Practice (CPMP/ICH-135/95). This trial was not commissioned and was peer reviewed for ethical and funding approval prior to submission.

Trial status
The first participant was randomised on 19 March 2019, and it is anticipated that the last participant will be recruited at the end of December 2021. Recruitment was...
stopped between March 2020 and July 2020, and severely limited until December 2020 due to the global COVID-19 pandemic. The most recent version of the protocol is V.1.2 dated November 2019.

**Dissemination plan**
The results of this study will be submitted for publication to peer-reviewed journals and will be presented at national and international conferences.

**Author affiliations**
1. Kolling Institute, The University of Sydney, Sydney, New South Wales, Australia
2. Kolling Institute, Northern Sydney Local Health District, Sydney, New South Wales, Australia
3. Department of Physiotherapy, South Western Sydney Local Health District, Sydney, New South Wales, Australia
4. School of Public Health, The University of Sydney, Sydney, New South Wales, Australia
5. Physiotherapy Department, Blacktown & Mount Druitt Hospital, Sydney, New South Wales, Australia
6. Department of Physiotherapy, Campbelltown Hospital, Sydney, New South Wales, Australia
7. Department of Physiotherapy, Liverpool Hospital, Sydney, New South Wales, Australia
8. Department of Physiotherapy, Bankstown Hospital, Sydney, New South Wales, Australia
9. Kolling Institute, The University of Sydney, Sydney, New South Wales, Australia
10. Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia
11. Institute for Musculoskeletal Health, The University of Sydney, Sydney, New South Wales, Australia
12. Institute of Bone and Joint Research, University of Sydney, Sydney, New South Wales, Australia

**Twitter** Catherine Sherrington @cathsherr

**Acknowledgements**
The authors acknowledge support from the health professionals, patients and staff at each of the sites.

**Contributors** LAH, JVG, HGW, JC, CGM, CS, MDJ, MLF and AJH were responsible for the design of the intervention and the trial. LAH, JVG, HGW, MLF, DAL, AJH, DAT, LS and MJU secured funding. AJH is responsible for the economic analysis, TEJL, JC, HGW, AB, JKC, KD and BAP are responsible for collecting data, LS, JJC, US, BAP, DW, KD, AB, MJT, MDJ and HGW are responsible for the sites. All authors have read and approved the final manuscript.

**Funding** This project has received funding through Australia’s Medical Research Future Fund Rapid Applied Research Translation Program grant awarded to Sydney Health Partners.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**
Hannah G Withers http://orcid.org/0000-0001-5319-7757
Catherine Sherrington http://orcid.org/0000-0001-8934-4368

**REFERENCES**
Late-life function & disability instrument. Available: https://geriatric toolkit.missouri.edu/funct/lifdi.htm [Accessed 05/05/2021].


